drugset / Trial / NCT00005835
N99-02: Melphalan and Buthionine Sulfoximine
Phase 1
Completed
31 enrolled
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of melphalan and buthionine sulfoximine followed by bone marrow or peripheral stem cell transplantation in treating children who have resistant or recurrent neuroblastoma.
Timeline
- Start
- 2001-08
- Primary completion
- 2014-12
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 62.5 mg/m2 | Intravenous |
| Subject | buthionine sulfoximine | Small molecule | 1 g/kg | Intravenous |